Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

    ... patients with refractory anemia with excess of blasts (RAEB) type 1, 18 patients with RAEB type 2 and four patients with ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. An update on the treatment of myelodysplastic syndromes.

    ... abnormalities, and the presence of bone marrow blasts . The only potentially curative treatment for MDS is hematopoietic ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Prognosis of myelodysplastic syndromes.

    ... that include morphological features, percentage of blasts , and clinical and molecular characteristics such as peripheral ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... three patients who relapsed on monotherapy with excess blasts at 12, 19, and 24 months, in whom lenalidomide was then resumed in ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... myeloid leukemia with 20% to 30% bone marrow blasts . METHODS: This secondary analysis of the AZA-001 phase 3 study ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. The search for better prognostic models in myelodysplastic syndromes.

    ... to acute myeloid leukemia based on the percentage of blasts , karyotype, and number of cytopenias, but the IPSS has several ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Paroxysmal nocturnal hemoglobinuria in pediatric patients.

    ... myelodysplastic features without developing excessive blasts or leukemic transformation. Thrombosis occurred in 6 patients. Five ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

    ... refractory anemia with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocitic leukaemia ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... At diagnosis, 126 patients (77%) had an excess of marrow blasts , and 95 patients (58%) had intermediate-2 or high-risk MDS according ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

    ... (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of anemia and ...

    Research Article last updated 07/20/2018 - 5:15pm.